Europe T-cell Therapy Market Size & Outlook, 2021-2028
Europe t-cell therapy market, 2018-2028 (US$M)
Related Markets
Europe t-cell therapy market highlights
- The Europe t-cell therapy market generated a revenue of USD 1,373.3 million in 2021.
- The market is expected to grow at a CAGR of 12.2% from 2022 to 2028.
- In terms of segment, commercialized was the largest revenue generating modality type in 2021.
- Commercialized is the most lucrative modality type segment registering the fastest growth during the forecast period.
- Country-wise, Germany is expected to register the highest CAGR from 2022 to 2028.
Europe data book summary
| Market revenue in 2021 | USD 1,373.3 million |
| Market revenue in 2028 | USD 3,066.7 million |
| Growth rate | 12.2% (CAGR from 2021 to 2028) |
| Largest segment | Commercialized |
| Fastest growing segment | Commercialized |
| Historical data covered | 2018 - 2020 |
| Base year for estimation | 2021 |
| Forecast period covered | 2022 - 2028 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Research, Commercialized |
| Key market players worldwide | Novartis AG ADR, Merck KGaA, Gilead Sciences Inc, Adaptimmune Therapeutics PLC ADR, Bluebird bio Inc, Sorrento Therapeutics Inc, Fate Therapeutics Inc, Pfizer Inc, Amgen Inc, Bristol-Myers Squibb Co |
Other key industry trends
- In terms of revenue, Europe region accounted for 21.5% of the global t-cell therapy market in 2021.
- Globally, North America is projected to lead the regional market in terms of revenue in 2028.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 8,113.5 million by 2028.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
T-cell Therapy Market Scope
T-cell Therapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe t-cell therapy market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to t-cell therapy market will help companies and investors design strategic landscapes.
Commercialized was the largest segment with a revenue share of 67.1% in 2021. Horizon Databook has segmented the Europe t-cell therapy market based on research, commercialized covering the revenue growth of each sub-segment from 2018 to 2028.
The European region is expected to follow closely behind the North American region in terms of revenue share. Post assessment by the UK’s National Institute for Health and Care Excellence, T-cell therapies, Yescarta and Kymriah, were approved by the EU in the year 2018. According to European Hematology Association in 2019, approximately 340 patients were treated with T-cell therapies in the European region, with a majority being treated during clinical trial evaluations.
It was also reported that in addition to the approved indications—B-cell lymphoma and B-cell ALL—the use of these therapies is being extended to other hematological diseases such as multiple myeloma, acute myeloid leukemia, and Hodgkin lymphoma.
In 2018, the European Medicines Agency (EMA) recommended marketing authorization for Kymriah and Yescarta, boosting adoption of T-cell therapies in the region. The therapies were the first to be approved through EMA Priority Medicines (PRIME) program, which has been specifically designed for the approval of innovative drug therapies.
Reasons to subscribe to Europe t-cell therapy market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe t-cell therapy market databook
-
Our clientele includes a mix of t-cell therapy market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe t-cell therapy market , including forecasts for subscribers. This continent databook contains high-level insights into Europe t-cell therapy market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
Partial client list
Europe t cell therapy market size, by country, 2018-2028 (US$M)
Europe T-cell Therapy Market Outlook Share, 2021 & 2028 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
